GlassScriptPhysician profile
Ramachandra Malya
NPI 1235171729
$311,686.65
in general payments reported to CMS, 2019-2025
14 companies · $6,033 in 2025
The $6,033 reported for 2025 was more than what 94% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,467 · 2020: $3,806 · 2021: $91K · 2022: $121K · 2023: $70K · 2024: $13K · 2025: $6,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $56K · Travel and Lodging: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,100 · Consulting Fee: $5,085 · Food and Beverage: $3,739 · Education: $40.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $56,175.00 |
| Travel and Lodging | $14,595.65 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,100.00 |
| Consulting Fee | $5,085.00 |
| Food and Beverage | $3,738.54 |
| Education | $40.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $284,721.48 | 2019-2023 | Krystexxa |
| Amgen INC. | $16,227.09 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Vifor Pharma, INC. | $7,248.52 | 2019-2022 | |
| Sobi, INC | $2,207.34 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $539.10 | 2022-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $333.67 | 2019-2024 | Auryxia, Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $244.27 | 2023-2025 | |
| Aurinia Pharma U.S., INC. | $63.47 | 2022-2024 | Lupkynis |
| Lilly USA, LLC | $31.02 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $17.81 | 2022 | |
| Fresenius USA Marketing, INC. | $15.27 | 2024 | |
| Sanofi-Aventis U.S. LLC | $13.27 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $12.48 | 2020 | |
| Indivior INC. | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramachandra Malya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.